About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma


Follicular Lymphoma >  Follicular Lymphoma abstracts - ASH 2012

Last update: 12/31/2012


Comments or Questions?

126 abstracts

Outcome reports

  1. Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma

    N=253 categorized based on their responses as using “active coping” (medical care decreases anxiety) or “avoidant coping” prefer to avoid medical care.   This grouping (and how it was determined) seems useful ... to see who could benefit from anti-anxiety drugs or life style practices that are thought to reduce stress, such as regular exercise.  Or who should "aim for the fences" with initial therapy of indolent lymphoma ... instead of management?
  2. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

    N=30 Rituxan-sensitive grade 1/2 FL.  Encouraging activity and safety profile.  Caveats: no control group, small study.  See for comment PAL
  3. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody

    Non-clinical but related to prior clinical results reported for CT-011
  4. Fludarabine, Mitoxantrone and Rituximab (FMR) Regimen in Previously Untreated Patients with Indolent Non-Hodgkin Lymphoma: Efficacy, Safety and PET Data On 285 Patients

    N = 285 untreated indolent lymphoma.  Encouraging outcomes long term. Caveat: retrospective design.
  5. Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute

    N = 55.  Caveats: no control group, mixed histologies (subtypes), immature time to events.
  6. A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/ Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

    N = 30; activity noted in follicular  Caveats: small study, no control group, mixed histologies (subtypes), safety profile good but not impressive.
  7. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

    n= 447 randomized patients, 436 received treatment
    BR n=221; R-CHOP/R-CVP n=215 [R-CHOP n=99; R-CVP n=116])

    Of these, 419 patients (BR n=213; R-CHOP/R-CVP n=206 [R-CHOP 97; R-CVP n=109]) were evaluable for efficacy. The randomized groups were well matched for age (median 60 and 58 years)

    CR% for NHL: B-R =31 % vs CHOP/CVP-R =25%   | MCL: 51 vs 24%
  8. Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL)

    N = 76 elderly with advanced FL, 75% CR rate; use of PCR to evaluate response; Caveats: preliminary.
  9. What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study "Refoll" by the Fondazione Italiana Linfomi (FIL) On 548 Patients

    N = 582 relapsed FL treated in various ways, multi-center.  Caveats: retrospective, Time to Next Treatment is a controversial endpoint.
  10. Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

    N = 58 untreated FL.  Caveats: does not inform about how OFA  compares to R-CHOP or R-B?
  11. Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

    N = 39  relapsed >2 treatments, 19 SLL, 11 LPL, 4 splenic MZL, 3 extranodal MZL and a 2 nodal MZL. Median age was 68 years (51-76) and 58% were male..  Caveats: mixed histologies.
  12. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

    n=103 untreated indolent lymphoma with need to treat, mixed histology, high CR rate and 2 year PFS for FL and MZL in particular.
  13. Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma

    N = 447  previously untreated indolent NHL or MCL - BR significantly results in better quality of life in this randomized controlled study
  14. Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up

    N = 15 with purine analog naïve, relapsed or refractory FL; some prolonged remissions.  Caveat: very small study.
  15. Long-Term Disease-Free Survival in Patients with Relapsed/Refractory Follicular Lymphoma After Autologous Stem Cell Transplantation

    N = 123  relapsed FL; approximately 50% free of progression at 44 mo; 30% achieved long term remission.   Caveat: retrospective analysis
  16. Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and Rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG))

    N = 85 early stage FL, untreated - median age 55. Caveats:  no control group; preliminary results.
  17. Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

    N = 201 treated with Thiotepa versus 578 with non-Thioptepa conditioning. 
  18. Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

    N = 313 with symptomatic FL, mostly previously untreated. 
  19. Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations

    N = 66 with measurable FL, treated and untreated, good activity, duration of response and safety but with some serious AEs; Caveat: single-arm study, mixed treatment history. 
  20. The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
  21. A Phase I Trial of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
  22. Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in NHL: Phase I Results
  23. Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection
  24. 90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for
  25. A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
  26. Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of "Fol-Brite"
  27. Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma, Final Report
  28. RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years
  29. Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma
  30. Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)
  31. Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory
  32. Patterns of Delivery of Chemoimmunotherapy to Patients with Follicular Lymphoma in the United States: Results of the National Lymphocare Study
  33. Meta Analysis of Grade 3 and/or 4 Toxicities in Follicular (FL) and Mantle Cell (MCL) Non-Hodgkin Lymphoma (NHL) Patients Receiving Maintenance Rituximab (MR): Impact of Schedule, Histology, and Induction Regimen
  34. A Novel Combination Therapy Based On the Genetics of Follicular Lymphoma
  35. In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines
  36. A Phase I Study of DCDT2980S an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
  37. An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin ( cd22,antibody-drug conjugate) in Patients with CD22-Positive B-Cell Non-Hodgkin’s Lymphoma: Preliminary Safety and Efficacy Data
  38. Rituximab +/- Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute
  39. Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin’s Lymphoma Receiving Radioimmunotherapy
  40. Phase I Study of Intravenous PI3K Inhibitor Bay 80-6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort
  41. Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma
  42. Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)
  43. Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs‑1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study
  44. The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study
  45. Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance
  46. Early Stage Follicular Lymphoma: Is There a Clinical Impact of First Line Treatment?
  47. Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin’s Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS)
  48. FDG-PET/CT Early After 90Y-Ibritumomab Tiuxetan Therapy Predicts Outcome in Relapsed or Refractory Indolent B-Cell Lymphoma
  49. Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients
  50. Full Dose Bendamustine (Treanda ®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma
  51. Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma
  52. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study
  53. Primary Refractory Disease in Non-Hodgkin’s Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy
  54. Phase 1b Study of TRU-016, an Anti-CD37 SMIPTM Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma
  55. Pharmacokinetic and Pharmacodynamic Analysis of Ocaratuzumab (AME-133v, is a Fc- and Fab-engineered humanized anti-CD20 monoclonal antibody) in 50 Patients with Relapsed Follicular Lymphoma and Low-Affinity FcγRIIIa (CD16a) Polymorphisms
  56. A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
  57. A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma
  58. Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin’s Lymphoma Treated with Splenectomy
  59. A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)
  60. Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
  61. Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)
  62. The Clinical Course of Patients with Follicular Lymphoma in the Rituximab Era: A Paradigm Shift
  63. Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis
  64. Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab
  65. Safety and Efficacy of High-Dose Cyclophosphamide, Etoposide, and Ranimustine (CEM) Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with High Risk De Novo Diffuse Large B-Cell Lymphoma or Diffuse Large B-Cell Lymphoma Associated with Follicular Lymphoma
  66. Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial
  67. Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study
  68. Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed


Other: Biology - preclinical, Risk factors,
Evaluating / Predicting Response

  1. Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies

    Comment: Markers for higher-risk disease can be useful for guiding therapy, but it doesn't necessarily modify the risk of the disease to change the marker by supplementation.

    Analogy:  A low number of sea birds on the coastline might be associated with the severity of a hurricane that is approaching the shore. Releasing more sea birds in the area would not change the behavior of the storm. 

    For a study to determine that normalizing vitamin D levels improves the behavior of the disease would require a study comparing this practice to observation.  Please note, it seems plausible to us (lay observers, non-scientists) that supplementing with vitamin D could also feed the growth of a disease ... if the disease is dependent on the vitamin for its growth, which might also explain the low serum levels of this vitamin in higher risk lymphoma?
  2. Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma
  3. High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy
  4. Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes
  5. Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma
  6. Iterative Germinal Center Re-Entries of Memory B-Cells with t(14;18) Translocation and Early Steps of Follicular Lymphoma Progression
  7. Clinicopathologic Analysis of Follicular Lymphoma (FL) Patients with Coexisting Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Rituximab-Containing Chemotherapy
  8. Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era
  9. Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource
  10. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody
  11. Serum Soluble LR11 Can Predict High FLIPI-2 Score in Follicular Lymphoma
  12. MEF2B Mutations Lead to De-Regulated Expression of the BCL6 Oncogene in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
  13. The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma
  14. "Early Lesion" of Follicular Lymphoma (FL) Precedes Clinically Overt FL: A Retrospective Study of Lymph Nodes (LNs) Obtained At Surgery with LNs Dissection for Preceding Cancer
  15. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience
  16. PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)
  17. Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL).
  18. Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
  19. Absolute Monocyte Count in Follicular Lymphoma Patients Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
  20. MIB-1 Labeling Index As a Prognostic Factor in Patients with Follicular Lymphoma Treated with R-CHOP Therapy
  21. Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis
  22. Detection of Leukemic Phase in Patients with Follicular Lymphoma At Diagnosis: A Rare Event Associated with Poor Prognosis
  23. Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study
  24. Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS)
  25. Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma
  26. Clinical Features of Newly Diagnosed CD25-Positive Follicular Lymphoma
  27. BCL2 Negative Follicular Lymphoma with BCL6 Gene Rearrangement Show Mutations of STAT6 DNA Binding Domain
  28. Remission Duration ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose Therapy and Autologous Stem Cell Rescue
  29. Influence of Lifestyle Factors On Expression of Tumor-Related Microenvironment T-Cells and Impact On Survival of Follicular Lymphoma (FL)
  30. The Transcriptional Profile of Follicular Lymphoma Associated Regulatory T-Cells (Tregs) Is More Consistent with Tregs Having a Germinal Center Localization and the Ability to Suppress Follicular Helper T-Cells
  31. Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
  32. The Impact of Race, Age, and Sex in Follicular Lymphoma (FL): A Comprehensive SEER Analysis in the Pre- and Post-Rituximab Eras
  33. Expression of Inhibitory Fc Receptor (FcγRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL)
  34. High Level of CD71 Expression On Neoplastic B Cells At Diagnosis Is Predictive of Overall Survival After Rituximab and Anthracyclines Based Regimen in Follicular Lymphoma
  35. FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma
  36. Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome
  37. Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma
  38. Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database
  39. Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma
  40. in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses
  41. Aid-Mediated Hypermutation of B-Cell Receptors with Subsequent Subclone Selection Define Biological Differences Between IgM-Expressing and Isotype-Switched Follicular Lymphoma
  42. Number of PD-1+/CD8+ Cells in Peripheral Blood of Patients with Lymphoma Reflects Tumor Burden, Lymphoma Subtype, Disease Phase and Is Significantly Higher Compared to Healthy Volunteers
  43. CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis
  44. Blood and Lymphatic Microenvironment As Prognostic Marker in Follicular Lymphoma
  45. T-Cell Profiling Shows Marked Differences in Gene Expression Between Tumour Infiltrating (TIL) and Peripheral Blood (PB) Antibody-Bead Selected T-Cells From Fresh Lymph Node and PB Samples in Follicular Non-Hodgkin's Lymphoma (FL): Possible implications for Immunomodulatory Therapy
  46. Effector and Regulatory T Cell Subsets in Follicular Lymphoma Tumors: Implications for Pathogenesis and Prognosis
  47. Quantitative Ultra-Deep Sequencing of Non-Coding Regions to Characterize Clonal Evolution in Follicular Lymphoma
  48. Mesenchymal Stromal Cells Support Follicular Lymphoma-Associated Follicular Helper T-Cells, in Part, Through an IL-6 and IL-21-Dependent Mechanism
  49. Deregulation of CCND1 or BCL2 in the Immature B-Cell Stage Determines the Resulting Lymphoma Histology
  50. Comparison of HLA Alleles in Follicular Lymphoma and Chronic Lymphocytic Leukemia Patients Referred for Allogeneic Stem Cell Transplantation
  51. The Functional Role of Acquired N-Linked Glycosylation Sites On Follicular Lymphoma B Cell Antigen Receptors
  52. Defining the Malignant Epigenome in Non-Hodgkin Lymphoma
  53. Hepatitis B Infection Is Associated with an Increased Risk of Non-Hodgkin Lymphoma: A Meta-Analysis
  54. In Vitro and in Vivo Effect of Sodium Metaarsenite (KML001) in Non-Hodgkin’s Lymphoma


See also Other Ways to Help


Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.